Predictive and Prognostic Value of ABO Blood Group in Patients Using Immune Checkpoint Inhibitor for Advanced Renal Cell Carcinoma

Basit Öğe Kaydı
dc.contributor.authorErgün, Yakup
dc.contributor.authorUrakçı, Zuhat
dc.contributor.authorYazıcı, Ozan
dc.contributor.authorİmamoğlu, Gökşen İnanç
dc.contributor.authorKahraman, Seda
dc.contributor.authorAçıkgöz, Yusuf
dc.contributor.authorUncu, Doğan
dc.date.accessioned2024-04-24T19:13:15Z
dc.date.available2024-04-24T19:13:15Z
dc.date.issued2022
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: We investigated the prognostic and predictive effects of the ABO blood group system on patients receiving immune checkpoint inhibitors for advanced renal cell carcinoma (RCC). Material and Methods: In this retrospective observational study, the data on the patients with known ABO blood group, who were administered nivolumab for mRCC, were reviewed. The tumor response rates and survival were analyzed based on the ABO blood group. Results: A total of 89 patients were included in the study. The median age of the patients was 57 (range: 24-83 years) years, and 67% (n=60) of the patients were male. Moreover, 43%, 18%, 9%, and 30% of the patients had blood groups A, B, AB, and O, respectively. Our study had a median follow-up time of 11 months. Although the groups did not differ significantly in progression-free survival (PFS) and overall survival (OS) according to the blood groups, patients who had the B blood type survived longer. For patients with blood types A, B, AB, and O, the median PFS was 5.3 months, 8.4 months, 3.7 months, and 7.8 months, respectively (p=0.8), and the median OS was 14.5 months, 20.3 months, 12.0 months, and 16.5 months, respectively (p=0.8). Conclusion: Although the groups did not differ significantly according to the ABO blood group, the patients with the B blood group survived relatively longer. These results suggested that further studies with more patients should be conducted.en_US
dc.identifier.doi10.37047/jos.2022-90679
dc.identifier.endpage106en_US
dc.identifier.issn2651-4532
dc.identifier.issue2en_US
dc.identifier.startpage100en_US
dc.identifier.trdizinid1123624
dc.identifier.urihttps://doi.org/10.37047/jos.2022-90679
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1123624
dc.identifier.urihttps://hdl.handle.net/11468/28495
dc.identifier.volume8en_US
dc.indekslendigikaynakTR-Dizin
dc.language.isoenen_US
dc.relation.ispartofJournal of oncological sciences
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titlePredictive and Prognostic Value of ABO Blood Group in Patients Using Immune Checkpoint Inhibitor for Advanced Renal Cell Carcinomaen_US
dc.titlePredictive and Prognostic Value of ABO Blood Group in Patients Using Immune Checkpoint Inhibitor for Advanced Renal Cell Carcinoma
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu